{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T05:14:38Z","timestamp":1773465278571,"version":"3.50.1"},"reference-count":136,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Institute of Clinical Pathology and Medical Research"},{"name":"Westmead Hospital"},{"name":"Australian Government Research Training Program (RTP) Scholarship"},{"name":"National Health and Medical Research Council of Australia"},{"name":"Cancer Council of New South Wales"},{"DOI":"10.13039\/501100001774","name":"University of Sydney","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001774","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Leukaemia Foundation of Australia"},{"name":"Leukemia and Lymphoma Society of the US"},{"name":"Rising Tide Foundation for Clinical Cancer Research Switzerland"}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.jcyt.2017.07.012","type":"journal-article","created":{"date-parts":[[2017,9,16]],"date-time":"2017-09-16T02:31:16Z","timestamp":1505529076000},"page":"1284-1301","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Cellular therapy for multiple pathogen infections after hematopoietic stem cell transplant"],"prefix":"10.1016","volume":"19","author":[{"given":"Gaurav","family":"Sutrave","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Blyth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2017.07.012_bib0010","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/bmt.2015.330","article-title":"Analysis of non-relapse mortality and causes of death over 15 years following allogeneic hematopoietic stem cell transplantation","volume":"51","author":"Tanaka","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0015","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood-2016-10-748426","article-title":"The cumulative burden of double-stranded DNA virus detection after allogeneic HCT is associated with increased mortality","volume":"129","author":"Hill","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0020","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1083-8791(03)00287-8","article-title":"Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies","volume":"9","author":"Boeckh","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0025","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1182\/blood-2002-11-3472","article-title":"Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation","volume":"102","author":"Hakki","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0030","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1182\/blood-2011-08-371971","article-title":"Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation","volume":"119","author":"Doubrovina","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0035","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.bbmt.2013.11.028","article-title":"Immune reconstitution after haploidentical hematopoietic stem cell transplantation","volume":"20","author":"Chang","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0040","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1080\/21505594.2016.1208866","article-title":"Immune reconstitution post allogeneic transplant and the impact of immune recovery on the risk of infection","volume":"7","author":"Mehta","year":"2016","journal-title":"Virulence"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0045","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.beha.2008.06.003","article-title":"Immune reconstitution and implications for immunotherapy following haematopoietic stem cell transplantation","volume":"21","author":"Williams","year":"2008","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0050","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nri2322","article-title":"The regulation of IgA class switching","volume":"8","author":"Cerutti","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0055","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/sj.bmt.1701655","article-title":"Serum levels of IL-7 in bone marrow transplant recipients: relationship to clinical characteristics and lymphocyte count","volume":"23","author":"Bolotin","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0060","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1182\/blood-2009-12-234096","article-title":"Immune reconstitution after allogeneic transplantation and expanding options for immunomodulation: an update","volume":"115","author":"Seggewiss","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0065","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/sj.bmt.1704966","article-title":"Immune restoration following hematopoietic stem cell transplantation: an evolving target","volume":"35","author":"Auletta","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0070","doi-asserted-by":"crossref","first-page":"5845","DOI":"10.1182\/blood.V124.21.5845.5845","article-title":"Multiplex PCR for virus infections after allogeneic hematopoietic stem cell transplantation","volume":"124","author":"Inazawa","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0075","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1086\/508173","article-title":"Seroprevalence of cytomegalovirus infection in the United States, 1988\u20131994","volume":"43","author":"Staras","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0080","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S1473-3099(04)01202-2","article-title":"Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments","volume":"4","author":"Gandhi","year":"2004","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0085","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1046\/j.1365-2141.2002.03515.x","article-title":"Prevention and treatment of viral infections in stem cell transplant recipients","volume":"118","author":"Ljungman","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0090","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1182\/blood-2002-03-0993","article-title":"Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity","volume":"101","author":"Boeckh","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0095","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.hoc.2010.11.011","article-title":"Cytomegalovirus in hematopoietic stem cell transplant recipients","volume":"25","author":"Ljungman","year":"2011","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0100","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/S2352-3026(15)00289-6","article-title":"Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study","volume":"3","author":"Green","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0105","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/sj.bmt.1704232","article-title":"Cytomegalovirus antigenemia and outcome of patients treated with pre-emptive ganciclovir: retrospective analysis of 241 consecutive patients undergoing allogeneic hematopoietic stem cell transplantation","volume":"32","author":"Yanada","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0110","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1182\/blood-2015-11-679639","article-title":"Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis","volume":"127","author":"Teira","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0115","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1473-3099(11)70024-X","article-title":"Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial","volume":"11","author":"Marty","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0120","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa1303688","article-title":"CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation","volume":"369","author":"Marty","year":"2013","journal-title":"NEJM"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0125","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1309533","article-title":"Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation","volume":"370","author":"Chemaly","year":"2014","journal-title":"NEJM"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0130","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.jcyt.2014.02.010","article-title":"The clinical and financial burden of preemptive management of CMV disease after allogeneic stem cell transplantation\u2014implications for preventative treatment approaches","volume":"16","author":"Jain","year":"2014","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0135","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1182\/blood.V95.7.2240","article-title":"Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation","volume":"95","author":"Broers","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0140","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1387\/ijdb.041947el","article-title":"The human T cell immune response to Epstein-Barr virus","volume":"49","author":"Landais","year":"2005","journal-title":"Int J Dev Biol"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0145","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1182\/blood.V98.4.972","article-title":"Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell\u2013depleted SCT","volume":"98","author":"van Esser","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0150","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/bmt.2008.386","article-title":"Second European Conference on Infections in, Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia","volume":"43","author":"Styczynski","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0155","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/1756-8722-6-94","article-title":"Diagnosis and treatment of viral diseases in recipients of allogeneic hematopoietic stem cell transplantation","volume":"6","author":"Lin","year":"2013","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0160","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/rmv.589","article-title":"Clinical features and treatment of adenovirus infections","volume":"18","author":"Lenaerts","year":"2008","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0165","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1086\/427513","article-title":"Immune reconstitution and clearance of human adenovirus viremia in pediatric stem-cell recipients","volume":"191","author":"Heemskerk","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0170","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/sj.bmt.1705645","article-title":"Reconstitution of adenovirus-specific cell-mediated immunity in pediatric patients after hematopoietic stem cell transplantation","volume":"39","author":"Myers","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0175","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jcv.2008.04.014","article-title":"Quantification of adenovirus DNA in unrelated donor hematopoietic stem cell transplant recipients","volume":"43","author":"Gustafson","year":"2008","journal-title":"J Clin Virol"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/176418","article-title":"Management of adenovirus in children after allogeneic hematopoietic stem cell transplantation","volume":"2013","author":"Ip","year":"2013","journal-title":"Adv Hematol"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0185","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1365-2141.2004.05218.x","article-title":"Adenovirus as an emerging pathogen in immunocompromised patients","volume":"128","author":"Leen","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0190","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/sj.bmt.1703798","article-title":"Cidofovir for adenovirus infections after allogeneic hematopoietic stem cell transplantation: a survey by the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation","volume":"31","author":"Ljungman","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0195","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.bbmt.2016.12.621","article-title":"Brincidofovir for asymptomatic adenovirus viremia in pediatric and adult allogeneic hematopoietic cell transplant recipients: a randomized placebo-controlled phase II trial","volume":"23","author":"Grimley","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0200","first-page":"S13","article-title":"Herpes zoster pathogenesis and cell-mediated immunity and immunosenescence","volume":"109","author":"Oxman","year":"2009","journal-title":"J Am Osteopath Assoc"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0205","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ijid.2003.09.006","article-title":"A review of the varicella vaccine in immunocompromised individuals","volume":"8","author":"Sartori","year":"2004","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0210","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.bbmt.2010.10.025","article-title":"High incidence of herpes zoster in nonmyeloablative hematopoietic stem cell transplantation","volume":"17","author":"Su","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0215","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2005-09-3624","article-title":"Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation\u2014a randomized double-blind placebo-controlled study","volume":"107","author":"Boeckh","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0220","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/jmv.23472","article-title":"Longitudinal study of seroprevalence and serostability of the human polyomaviruses JCV and BKV in organ transplant recipients","volume":"85","author":"Antonsson","year":"2015","journal-title":"J Med Virol"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0225","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1097\/TP.0b013e31823328c0","article-title":"BK virus-specific T cells for use in cellular therapy show specificity to multiple antigens and polyfunctional cytokine responses","volume":"92","author":"Blyth","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0230","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.jcyt.2014.04.003","article-title":"Cellular immunotherapy for patients with reactivation of JC and BK polyomaviruses after transplantation","volume":"16","author":"Mani","year":"2014","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0235","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.bbmt.2015.12.009","article-title":"Cidofovir in the treatment of BK virus-associated hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation","volume":"22","author":"Philippe","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0240","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1128\/JVI.01737-09","article-title":"Leflunomide inhibition of BK virus replication in renal tubular epithelial cells","volume":"84","author":"Bernhoff","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0245","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.antiviral.2011.07.012","article-title":"Fluoroquinolones inhibit human polyomavirus BK (BKV) replication in primary human kidney cells","volume":"92","author":"Sharma","year":"2011","journal-title":"Antiviral Res"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0250","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/j.bbmt.2010.12.700","article-title":"Efficacy and safety of ciprofloxacin for prophylaxis of polyomavirus BK virus\u2013associated hemorrhagic cystitis in allogeneic hematopoietic stem cell transplantation recipients","volume":"17","author":"Miller","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0255","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1159\/000345852","article-title":"Efficacy and safety of leflunomide for the treatment of BK virus-associated hemorrhagic cystitis in allogeneic hematopoietic stem cell transplantation recipients","volume":"130","author":"Chen","year":"2013","journal-title":"Acta Haematol"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0260","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1128\/CMR.18.1.217-245.2005","article-title":"Update on human herpesvirus 6 biology, clinical features, and therapy","volume":"18","author":"De Bolle","year":"2005","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0265","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.coviro.2014.10.001","article-title":"Immune response to HHV-6 and implications for immunotherapy","volume":"9","author":"Becerra","year":"2014","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0270","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jcv.2015.09.013","article-title":"A fatal case of acute HHV-6 myocarditis following allogeneic haemopoietic stem cell transplantation","volume":"72","author":"Brennan","year":"2015","journal-title":"J Clin Virol"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0275","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1086\/367677","article-title":"Human Herpesvirus (HHV)-6 and HHV-7: two closely related viruses with different infection profiles in stem cell transplantation recipients","volume":"187","author":"Boutolleau","year":"2003","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0280","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1016\/S1386-6532(06)70018-X","article-title":"Human herpesvirus-6 infection in solid organ and stem cell transplant recipients","volume":"37","author":"Ljungman","year":"2006","journal-title":"J Clin Virol"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0285","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/QCO.0b013e3283553362","article-title":"Human herpesvirus 6 (HHV-6) disease in the setting of transplantation","volume":"25","author":"Zerr","year":"2012","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0290","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1086\/651263","article-title":"Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001\u20132006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database","volume":"50","author":"Kontoyiannis","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0295","doi-asserted-by":"crossref","first-page":"218","DOI":"10.3109\/00365548.2014.985709","article-title":"Invasive fungal infections in pediatric hematopoietic stem cell transplant patients","volume":"47","author":"Simms-Waldrip","year":"2015","journal-title":"Infect Dis"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0300","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.idc.2010.01.002","article-title":"Fungal infections in transplant and oncology patients","volume":"24","author":"Person","year":"2010","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0305","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jmii.2015.01.002","article-title":"Incidence and risk factors of probable and proven invasive fungal infection in adult patients receiving allogeneic hematopoietic stem cell transplantation","volume":"49","author":"Liu","year":"2016","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0310","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.4049\/jimmunol.1400776","article-title":"Identification of immunogenic antigens from Aspergillus fumigatus by direct multiparameter characterization of specific conventional and regulatory CD4+ T cells","volume":"193","author":"Bacher","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0315","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1182\/blood-2002-01-0265","article-title":"Analysis of T-cell responses to Aspergillus fumigatus antigens in healthy individuals and patients with hematologic malignancies","volume":"100","author":"Hebart","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0320","doi-asserted-by":"crossref","first-page":"S229","DOI":"10.1080\/13693780600760773","article-title":"Th1\/Th2 in aspergillosis","volume":"44","author":"Stevens","year":"2006","journal-title":"Med Mycol"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0325","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0074326","article-title":"Characterization of specific immune responses to different Aspergillus antigens during the course of invasive aspergillosis in hematologic patients","volume":"8","author":"Potenza","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0330","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1182\/blood-2003-02-0456","article-title":"Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning","volume":"102","author":"Fukuda","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0335","first-page":"381","article-title":"Newer antifungal agents micafungin and voriconazole for fungal infection prevention during hematopoietic cell transplantation: a meta-analysis","volume":"20","author":"Xu","year":"2016","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0340","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/myc.12222","volume":"57","author":"Abidi","year":"2014","journal-title":"Mycoses"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0345","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1128\/CMR.18.1.44-69.2005","article-title":"Aspergillus infections in transplant recipients","volume":"18","author":"Singh","year":"2005","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0350","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.bbmt.2016.05.014","article-title":"Risk factors and utility of a risk-based algorithm for monitoring cytomegalovirus, epstein-barr virus, and adenovirus infections in pediatric recipients after allogeneic hematopoietic cell transplantation","volume":"22","author":"Rustia","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0355","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/jmv.24161","article-title":"Large-scale multiplex polymerase chain reaction assay for diagnosis of viral reactivations after allogeneic hematopoietic stem cell transplantation","volume":"87","author":"Inazawa","year":"2015","journal-title":"J Med Virol"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0360","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/j.1399-3046.2009.01226.x","article-title":"Multiple viral infections post-hematopoietic stem cell transplantation are linked to the appearance of chronic GVHD among pediatric recipients of allogeneic grafts","volume":"14","author":"Olkinuora","year":"2010","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0365","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/j.1399-3046.2010.01325.x","article-title":"Cytomegalovirus, adenovirus, and polyomavirus co-infection among pediatric recipients of allogeneic stem cell transplantation: characteristics and outcome","volume":"14","author":"Watcharananan","year":"2010","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0370","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/23744235.2016.1210821","article-title":"Viremic co-infections in children with allogeneic haematopoietic stem cell transplantation are predominated by human polyomaviruses","volume":"49","author":"Koskenvuo","year":"2017","journal-title":"Infect Dis"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0375","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1182\/blood.V126.23.3296.3296","article-title":"Double-Stranded DNA (dsDNA) viral infections among allogeneic Hematopoietic Cell Transplant (HCT) recipients in the first year after transplant","volume":"126","author":"Schabert","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0380","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1056\/NEJM199404283301703","article-title":"Infusions of donor leukocytes to treat Epstein-Barr virus\u2013associated lymphoproliferative disorders after allogeneic bone marrow transplantation","volume":"330","author":"Papadopoulos","year":"1994","journal-title":"NEJM"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0385","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1146\/annurev-immunol-032414-112326","article-title":"The immunology of Epstein-Barr virus\u2013induced disease","volume":"33","author":"Taylor","year":"2015","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0390","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1128\/CMR.00034-08","article-title":"Immunobiology of human cytomegalovirus: from bench to bedside","volume":"22","author":"Crough","year":"2009","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0395","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1365-2141.2006.06108.x","article-title":"Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation","volume":"134","author":"Feuchtinger","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0400","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM199510193331603","article-title":"Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor","volume":"333","author":"Walter","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0405","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1182\/blood.V91.8.2925.2925_2925_2934","article-title":"Epstein-Barr Virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease","volume":"91","author":"Roskrow","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0410","doi-asserted-by":"crossref","first-page":"4360","DOI":"10.1182\/blood-2010-01-262089","article-title":"Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation","volume":"116","author":"Feuchtinger","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0415","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1182\/blood-2009-08-236356","article-title":"Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells","volume":"115","author":"Moosmann","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0420","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.bbmt.2007.02.004","article-title":"Ex Vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation","volume":"13","author":"Micklethwaite","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0425","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1182\/blood-2003-05-1433","article-title":"Generation of CMV-specific T lymphocytes using protein-spanning pools of pp65-derived overlapping pentadecapeptides for adoptive immunotherapy","volume":"105","author":"Trivedi","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0430","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1182\/blood-2008-06-161695","article-title":"Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modified dendritic cells after allogeneic hemopoietic stem cell transplantation","volume":"112","author":"Micklethwaite","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0435","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/nm1475","article-title":"Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals","volume":"12","author":"Leen","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0440","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1038\/mt.2009.140","article-title":"Nucleofection of DCs to generate multivirus-specific T cells for prevention or treatment of viral infections in the immunocompromised host","volume":"17","author":"Gerdemann","year":"2009","journal-title":"Mol Ther"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0445","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/INF.0b013e318182026f","article-title":"Infusion of cytomegalovirus specific cytotoxic T lymphocytes from a sero-negative donor can facilitate resolution of infection and immune reconstitution","volume":"28","author":"Horn","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0450","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.3324\/haematol.2010.039099","article-title":"Successful generation of primary virus-specific and anti-tumor T-cell responses from the naive donor T-cell repertoire is determined by the balance between antigen-specific precursor T cells and regulatory T cells","volume":"96","author":"Jedema","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0455","doi-asserted-by":"crossref","first-page":"285ra63","DOI":"10.1126\/scitranslmed.aaa2546","article-title":"CMV-specific T cells generated from na\u00efve T cells recognize atypical epitopes and may be protective in vivo","volume":"7","author":"Hanley","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0460","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/CJI.0b013e3181c0c3cb","article-title":"Accelerated production of antigen-specific T-cells for pre-clinical and clinical applications using Gas-permeable Rapid Expansion cultureware (G-Rex)","volume":"33","author":"Vera","year":"2010","journal-title":"J Immunother"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0465","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1084\/jem.20040613","article-title":"Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers","volume":"202","author":"Cobbold","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0470","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/j.1537-2995.2010.02940.x","article-title":"Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation","volume":"51","author":"Schmitt","year":"2011","journal-title":"Transfusion"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0475","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/cid\/ciq042","article-title":"Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation","volume":"52","author":"Peggs","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0480","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1093\/cid\/cis625","article-title":"Rapid salvage treatment with virus-specific T cells for therapy-resistant disease","volume":"55","author":"Uhlin","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0485","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/CJI.0b013e31826e35f6","article-title":"Effective treatment of refractory CMV reactivation after allogeneic stem cell transplantation with in vitro-generated CMV pp65-specific CD8+ T-cell lines","volume":"35","author":"Meij","year":"2012","journal-title":"J Immunother"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0490","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1200\/JCO.2011.39.8495","article-title":"Adoptive transfer of Epstein-Barr Virus (EBV) nuclear antigen 1\u2013specific T cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation","volume":"31","author":"Icheva","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0495","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1182\/blood-2014-06-573725","article-title":"Adoptive T-cell therapy with hexon-specific Th1 cells as a treatment of refractory adenovirus infection after HSCT","volume":"125","author":"Feucht","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0500","doi-asserted-by":"crossref","DOI":"10.1038\/leu.2017.16","article-title":"Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT","author":"Neuenhahn","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0505","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/sj.bmt.1700883","article-title":"Unsuccessful CTL transfusion in a case of post-BMT Epstein-Barr virus-associated lymphoproliferative disorder (EBV-LPD)","volume":"20","author":"Imashuku","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0510","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.1182\/blood.V91.10.3654","article-title":"Semiquantitative Epstein-Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation","volume":"91","author":"Lucas","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0515","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1182\/blood.V95.3.807.003k24_807_814","article-title":"Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells","volume":"95","author":"Gustafsson","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0520","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1182\/blood.V99.11.3916","article-title":"Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy","volume":"99","author":"Einsele","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0525","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/S0140-6736(03)14634-X","article-title":"Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines","volume":"362","author":"Peggs","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0530","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.1182\/blood-2005-05-1775","article-title":"Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation","volume":"106","author":"Perruccio","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0535","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1111\/j.1600-6143.2007.01823.x","article-title":"Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation","volume":"7","author":"Comoli","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0540","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood-2009-08-239186","article-title":"Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients","volume":"115","author":"Heslop","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0545","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/bmt.2010.221","article-title":"Polyomavirus JC-targeted T-cell therapy for progressive multiple leukoencephalopathy in a hematopoietic cell transplantation recipient","volume":"46","author":"Balduzzi","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0550","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/CJI.0b013e31824300a2","article-title":"Adoptive immunotherapy with CMV-specific cytotoxic T lymphocytes for stem cell transplant patients with refractory CMV infections","volume":"35","author":"Bao","year":"2012","journal-title":"J Immunother"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0555","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/j.bbmt.2015.05.015","article-title":"Immunotherapy with donor T cells sensitized with overlapping pentadecapeptides for treatment of persistent cytomegalovirus infection or viremia","volume":"21","author":"Koehne","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0560","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1172\/JCI81229","article-title":"Outcomes of acute leukemia patients transplanted with naive T cell\u2013depleted stem cell grafts","volume":"125","author":"Bleakley","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0565","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1182\/blood-2006-02-001909","article-title":"Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation","volume":"108","author":"Amrolia","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0570","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.bbmt.2011.05.019","article-title":"Selectively T cell-depleted allografts from HLA-matched sibling donors followed by low-dose posttransplantation immunosuppression to improve transplantation outcome in patients with hematologic malignancies","volume":"17","author":"Mielke","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0575","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.bcmd.2007.06.022","article-title":"Photodynamic purging of alloreactive T cells for adoptive immunotherapy after haploidentical stem cell transplantation","volume":"40","author":"Perruccio","year":"2008","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0580","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1182\/blood.V128.22.1226.1226","article-title":"Donor lymphocytes depleted of Alloreactive T-Cells (ATIR101) Improve Event-Free Survival (GRFS) and Overall survival in a T-cell depleted haploidentical HSCT: phase 2 trial in patients with AML and ALL","volume":"128","author":"Roy","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0585","doi-asserted-by":"crossref","first-page":"4392","DOI":"10.1182\/blood-2007-08-104471","article-title":"A clinical-scale selective allodepletion approach for the treatment of HLA-mismatched and matched donor-recipient pairs using expanded T lymphocytes as antigen-presenting cells and a TH9402-based photodepletion technique","volume":"111","author":"Mielke","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0590","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1016\/j.bbmt.2011.05.017","article-title":"Immune reconstitution in recipients of photodepleted HLA-identical sibling donor stem cell transplantations: T cell subset frequencies predict outcome","volume":"17","author":"McIver","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0595","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1182\/blood-2012-08-448977","article-title":"Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation","volume":"121","author":"Blyth","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0600","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1182\/blood.V97.4.835","article-title":"An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs","volume":"97","author":"Gottschalk","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0605","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.jcyt.2016.08.010","article-title":"Human parainfluenza virus-3 can be targeted by rapidly ex vivo expanded T lymphocytes","volume":"18","author":"McLaughlin","year":"2016","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0610","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3109\/14653249.2011.613932","article-title":"In vitro generation of influenza-specific polyfunctional CD4+ T cells suitable for adoptive immunotherapy","volume":"14","author":"Gaundar","year":"2012","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0615","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1097\/MPH.0b013e3181bf5e2d","article-title":"Adoptive transfer of cytomegalovirus\/Epstein-Barr virus-specific immune effector cells for therapeutic and preventive\/preemptive treatment of pediatric allogeneic cell transplant recipients","volume":"32","author":"Dong","year":"2010","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0620","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1182\/blood-2009-07-232454","article-title":"Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation","volume":"114","author":"Leen","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0625","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1038\/mt.2013.151","article-title":"Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant","volume":"21","author":"Gerdemann","year":"2013","journal-title":"Mol Ther"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0630","doi-asserted-by":"crossref","first-page":"242ra83","DOI":"10.1126\/scitranslmed.3008825","article-title":"Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT","volume":"6","author":"Papadopoulou","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0635","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/j.jcyt.2015.07.005","article-title":"Addition of varicella zoster virus-specific T cells to cytomegalovirus, Epstein-Barr virus and adenovirus tri-specific T cells as adoptive immunotherapy in patients undergoing allogeneic hematopoietic stem cell transplantation","volume":"17","author":"Ma","year":"2015","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0640","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1038\/mt.2012.130","article-title":"Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections","volume":"20","author":"Gerdemann","year":"2012","journal-title":"Mol Ther"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0645","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2003-05-1513","article-title":"Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses","volume":"103","author":"Peggs","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0650","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.1182\/blood-2013-02-486324","article-title":"Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation","volume":"121","author":"Leen","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0655","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2006-12-063008","article-title":"Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial","volume":"110","author":"Haque","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0660","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S0140-6736(02)09672-1","article-title":"Treatment of Epstein-Barr-virus\u2013positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells","volume":"360","author":"Haque","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0665","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/TP.0b013e3181d7c424","article-title":"Allogeneic T-cell therapy for Epstein-Barr virus-positive posttransplant lymphoproliferative disease: long-term follow-up","volume":"90","author":"Haque","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0670","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1365-2141.2011.08579.x","article-title":"Third-party virus-specific T cells eradicate adenoviraemia but trigger bystander graft-versus-host disease","volume":"154","author":"Qasim","year":"2011","journal-title":"Br J Haematol"},{"issue":"23","key":"10.1016\/j.jcyt.2017.07.012_bib0675","doi-asserted-by":"crossref","first-page":"5045","DOI":"10.1182\/blood-2010-04-281873","article-title":"Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes","volume":"116","author":"Barker","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0680","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/bjh.13051","article-title":"Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease","volume":"167","author":"Vickers","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jcyt.2017.07.012_bib0685","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1182\/blood.V126.23.623.623","article-title":"Third-party donor virus-specific t cells are efficacious in the treatment of refractory viral infection following allogeneic HSCT, but may not persist post-infusion","volume":"126","author":"Withers","year":"2015","journal-title":"Blood"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324917306576?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324917306576?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T01:33:30Z","timestamp":1761442410000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324917306576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":136,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S1465324917306576"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2017.07.012","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cellular therapy for multiple pathogen infections after hematopoietic stem cell transplant","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2017.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2017 Published by Elsevier Inc. on behalf of International Society for Cellular Therapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}